US Food and Drug Administration accepts New Drug Application for daprodustat

Regulatory submission for the treatment of anaemia of chronic kidney disease based on the ASCEND phase III clinical trial programme, consisting of five trials that all met their primary efficacy and safety endpoints in non-dialysis and dialysis patients US FDA regulatory submission acceptance is the third major regulatory milestone for daprodustat

Related Keywords

Japan ,United States ,United Kingdom ,American , ,Glaxosmithkline ,European Medicines Agency ,Drug Administration ,American Society Of Nephrology Kidney Week ,London United ,New Drug Application ,Nobel Prize Winning ,Prescription Drug User Fee Act ,New England Journal ,American Society ,Kidney Week ,Anaemia Studies ,Anatomy ,Cardiovascular Disease ,Diabetes ,Disease ,Medicine ,Nasdaq ,Obesity ,Pharmaceuticals ,Acetic Acids ,Assessment Of Kidney Function ,Branches Of Biology ,Chronic Kidney Disease ,Daprodustat ,Dialysis ,Epoetin Alfa ,Hif Prolyl Hydroxylase Inhibitor ,Hypoxia Inducible Factor ,Kidney Diseases ,